Applicant: Brian Smith, et al. Serial No.: 10/576,849 Filed: April 9, 2007 Page: 3 of 24

Amendments to the Claims:

Please cancel claims 25 and 32 and add new claims 49-56. Please amend claims 1-9, 11-15, 17-19, 21, 23-24, 26-31, and 48 as follows. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula (I):

or pharmaceutically acceptable salt thereof, wherein:

X is O, S, SO, SO₂, CO, COO, NR⁷, CONR⁷, SONR⁷, SO₂NR⁷, NR²CONR⁷ or is absent; Y is C₁-C₁, alkylenyl or is absent, wherein Y is optionally substituted by halo, C₁-C₄

alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino:

Z is O. S. SO. SO₂ or absent:

R1 is H, C1-C2 alkyl, C2-C2 cycloalkyl, or C1-C2 haloalkyl;

R2 is C1-C2 alkyl or C1-C2 haloalkyl;

R3 is H, C1-C2 alkyl, or C1-C2 haloalkyl;

or R² and R³ together with the C atom to which they are attached form a C₃-C₇ cycloalkyl ring:

 R^4 , R^3 , and R^4 are each, independently, H, halo, C_1C_2 alloyl, C_1C_2 haloully, I, C_1C_3 alloyl, thereozyl, betterocyloallyl, hydroxy, mercapto, C_1C_2 alloyl, C_1C_3 his his allows, C_1C_4 his allows C_1C

Applicant: Brian Smith, et al. Serial No.: 10/576,849 Filed: April 9, 2007 Page: 4 of 24

R7 is H, C1-C4 alkyl, or C1-C4 haloalkyl;

R³ and R⁹ are each, independently, H, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₇ cycloalkyl, cycloalkyl, aryl, or arylalkyl;

or R⁸ and R⁹ together with the N atom to which they are attached form a 5- or 6membered heterocycloalkyl group;

 $R^{10} \ is \ H, \ C_1 - C_4 \ alkyl, \ C_3 - C_7 \ cycloalkyl, \ cycloalkylalkyl, \ aryl, \ arylalkyl, \ heteroaryl, \ or \ heterocycloalkyl;$

 R^{11} is H, C_1 - C_4 alkyl, C_3 - C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

At is any l or heterouryl, each optionally substituted by one or more halo, symmo, nitro, C_1 - C_2 alixyl, C_2 - C_3 halosalkyl, C_2 - C_4 alixenyl, C_2 - C_4 alixynyl, any l, heteroxyl- C_2 - C_3 - C_4 alixeny, C_2 - C_4 -

or Ar together with Y and Z form a benze-fused cycloalityl or benze-fused heatercycloalityl group, each optionally substituted by one or more halo, cyano, nitro, C₁-C₆ attercycloalityl, C₁-C₆ haloslityl, C₂-C₆ attenyl, C₂-C₆ alleynl, anyl, heterocycloalityl, hydroxy, C₂-C₆ attenyl, C₂-C₆ haloslitoxy, C₃-C₇ cycloalityloxy, netrearcycloalityl, hydroxy, C₂-C₆ attenyl, C₂-C₆ haloslitoxy, C₃-C₇ thiocycloalityloxy, mercapto, C₃-C₆ thioslitoxy, C₃-C₇ thiocycloalityloxy, thiotheroxyloxy, C₃-C₆ attenyl, C₃-C₆ thioslitoxy, thioheteroxyloxy, C₃-C₆ attenyl, C₃-C₆ attenyl, C₃-C₆ haloslitylauffinyl, C₃-

 $R^{12} \ is \ H, \ C_1\text{-}C_4 \ alkyl, \ C_2\text{-}C_7 \ cycloalkyl, \ cycloalkylalkyl, \ aryl, \ arylalkyl, \ heteroaryl, \ or \ heterocycloalkyl;$

 R^{13} is H, C_1 - C_4 alkyl, C_5 - C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl; and

 R^{14} and R^{15} are each, independently, H, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_2 - C_7 cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl;

Applicant : Brian Smith, et al. Serial No. : 10/576,849 Filed : April 9, 2007 Page : 5 of 24

> or R ¹⁴ and R ¹⁵ together with the N atom to which they are attached form a 5- or 6membered heteroeveloalkyl group,

with the provisos:

a) — when Ar-Z-Y-X is bonded at position 7 or 8, and X is O, S or NR²; Y is unsubstituted C₁. C₁₀ all VienV or absent, and Z is absent, then Ar is substituted;

- b) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is aryl or aryl substituted with 1 substituent selected from the group consisting of C₁₊₂ alkyl, halogen, perhaloslicyl, and alkoxy, then said aryl is further substituted with one substituent other than a substituent from the group consisting of C₂₊₂ alkyl, halogen, perhaloslicyl, and alkoxy.
- c) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is aryl substituted with 2 substituents selected from C₁₋₈ alkyl, halogen, perhaloalkyl, and alkoxy, then said aryl is further substituted with at least one substituent;
- d) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is heteroaryl or heteroaryl substituted with 1 substituent selected from the group consisting of halogen and C₁₋₄ alkyl, then said heteroaryl is further substituted with one substituent other than a substituent from the group consisting of halogen and C₁₋₄ alkyl; and
- e) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is heteroaryl substituted with 2 substituents selected from halogen and C₁₋₈ alkyl, then said heteroaryl is further substituted with at least one substitutes.
- (Currently amended) The compound of claim 1 or pharmaceutically acceptable salt thereof, wherein X is 0, NR⁷, CONR⁷, or absent.
- (Currently amended) The compound of claim 1 or pharmaceutically acceptable salt thereof, wherein X is CO.
- (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Ar is phenyl.
- (Currently amended) The compound of claim I_x or pharmaceutically acceptable salt thereof, wherein R¹ is H.

Applicant : Brian Smith, et al. Attorney's Docket No.: 20750-Serial No. - 10/576.849 0048151/076 US2 PCT

Serial No.: 10/576,849 Filed: April 9, 2007 Page: 6 of 24

 (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R² is C₁-C₄ alkyl.

- (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R² is methyl.
- (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R³ is H.
- (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R⁴, R⁴, and R⁶ are each, independently, H, halo, C₁-C₈ alkyl, C₁-C₈ haloalkyl, or hydroxy.
- (Original) The compound of claim 1 having Formula (IIa):

or pharmaceutically acceptable salt thereof.

11. (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

wherein:

X is O, CO, S, SO, SO₂, NR⁷, CONR⁷ or is absent;

Y is C_1 - C_4 alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1 - C_4 alkoxy, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkyl, C_1 - C_6 haloalkyl, hydroxy, carboxy, amino, alkylamino, or dialkylamino:

Z is O. S. or absent:

R1 is H or C1-C8 alkyl;

Applicant: Brian Smith, et al. Serial No.: 10/576,849 Filed: April 9, 2007 Page: 7 of 24

R2 is C+-C+ alkyl:

R3 is H, C1-C2 alkyl, or C1-C2 haloalkyl;

R⁴, R⁵, and R⁶ are each, independently, H, halo, C₁-C₄ alkyl, C₁-C₄ haloalkyl, hydroxy, mercapto, C₁-C₄ alkoxy, or C₁-C₈ haloalkoxy, and

Ar is phenyl or pyridyl optionally substituted by one or more halo, cyano, nitro, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, C₃-C₇ cycloalkyl, heterocycloalkyl, hydroxy, C₁-C₆ alkoxy, C₁-C₈ haloalkoxy, COR¹², COOR¹³, NR³(R¹⁵;

 (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

X is CO:

Y is C1-C8 alkylenyl or absent;

R1 is H or C1-C2 alkvl;

R2 is C1-C4 alkyl;

R3 is H. C1-C2 alkyl, or C1-C2 haloalkyl;

 R^4 , R^5 , and R^6 are each, independently, H_s halo, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, hydroxy, mercapto, C_1 - C_4 alkoxy, or C_1 - C_4 haloalkoxy; and

Ar is phenyl substituted by one or more halo, cyano, nitro, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, aryl, heteroaryl, C_3 - C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1 - C_4 alkoxy, or C_1 - C_6 haloalkoxy.

 (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

X is NR7;

 Applicant :
 Brian Smith, et al.
 Attorney's Docket No.; 20750

 Serial No. :
 10/576,849
 0048US1/076.US2.PCT

Serial No. : 10/576,849 Filed : April 9, 2007 Page : 8 of 24

Y is C1-C6 alkylenyl;

Z is absent:

R1 is H or C-C alkyl:

R2 is Cr-Cr alkyl:

R3 is H. C.-C. alkyl. or C.-C. haloalkyl:

R⁴, R⁵, and R⁶ are each, independently, H, halo, C₁-C₄ alkyl, C₁-C₄ haloalkyl, hydroxy, mercapto, C₁-C₄ alkoxv, or C₁-C₆ haloalkoxv; and

Ar is phenyl substituted by one or more halo, cyano, nitro, C_1 – C_4 alkyl, C_1 – C_6 haloalkyl, C_2 – C_6 alkenyl, C_2 – C_6 alkynyl, aryl, heteroaryl, C_2 – C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1 – C_6 alkoxy, C_1 – C_6 haloalkoxy, COR^{12} , $COOR^{13}$, $NR^{16}R^{15}$.

or Ar together with Y and Z form a benzo-fused cycloalkyl optionally substituted by one or more halo, cyano, nitro, Cr-C₂ alkyl, Cr-C₃ haloalkyl, Cr-C₄ alkenyl, Cr-C₆ alkynyl, aryl, heteroaryl, C₂-C₇, cycloalkyl, heterocycloalkyl, hydroxy, Cr-C₆ alkoxy, Cr-C₆ haloalkoxy, COCR², NR²R².

14. (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

X is CONR7:

Y is C1-C6 alkylenyl or is absent;

Z is absent;

R1 is H or C1-C2 alkyl;

R2 is C1-C4 alkyl;

R3 is H, C1-C2 alkyl, or C1-C2 haloalkyl;

 R^4 , R^5 , and R^6 are each, independently, H, halo, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, hydroxy, mercapto, C_1 - C_4 alkoxy, or C_1 - C_4 haloalkoxy; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_2 - C_4 alkenyl, C_2 - C_5 alkynyl, aryl, heteroaryl, C_2 - C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1 - C_5 alkoxy, C_1 - C_6 haloalkoxy, COR^{12} , $COOR^{13}$, NR^{14} c N^{15} .

 (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

Applicant : Brian Smith, et al. Serial No.: 10/576,849 Filed : April 9, 2007 Page : 9 of 24

X is absent:

Y is C1-C6 alkylenyl;

Z is absent:

R1 is H or C1-C8 alkyl;

R2 is C1-C4 alkyl;

R3 is H, C1-C2 alkyl, or C1-C2 haloalkyl;

R4, R5, and R6 are each, independently, H, halo, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, mercapto, C1-C4 alkoxy, or C1-C6 haloalkoxy; and

Ar is phenyl or pyridyl optionally substituted by one or more halo, cyano, nitro, C - Cs alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, C1-C2 cycloalkyl, heterocyclosikyl, hydroxy, Cr-Ce alkoxy, Cr-Ce haloalkoxy, COR12, COOR13, NR14R15,

16. (Original) The compound of claim 1 having Formula (IIb):

or pharmaceutically acceptable salt thereof.

(Currently amended) The compound of claim 16, or pharmaceutically acceptable salt thereof, 17. wherein:

X is O. NR7, or is absent:

Y is C1-C4 alkylenyl or is absent, wherein Y is ontionally substituted by halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z. is O. S. or absent: R1 is H or C1-C8 alkyl;

R2 is Ca-Ca alkyl:

R3 is H:

Applicant: Brian Smith, et al. Serial No.: 10/576,849 Filed: April 9, 2007 Page: 10 of 24

 R^1 , R^2 , and R^6 are each, independently, H, halo, C_1 - C_2 alicyt, C_1 - C_3 halosityt, C_2 - C_4 alicenyt, C_1 - C_4 -

Ar is phenyl or pyridyl, each optionally substituted by one or more halo, cyano, nitro, $C_1 - C_2$ alixyl, $C_1 - C_3$ alixyl, $C_1 - C_4$ alixyl, aryl, heteroaryloxy, $C_1 - C_4$ alixyl, $C_1 - C_4$ alixyl, thioaryloxy, thioaryloxy, $C_1 - C_4$ alixylsulfinyl, $C_1 - C_4$ al

18. (Currently amended) The compound of claim 16, or pharmaceutically acceptable salt thereof, wherein:

X is absent:

Y is methylene or ethylene;

Z. is absent:

R1 is H or Cr-Ca alkyl:

R2 is methyl or ethyl:

R3 is H:

R4 and R6 are both H;

 R^5 is halo, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, hydroxy, C_1 - C_8 alkoxy, C_1 - C_8 haloalkoxy, evano, nitro, or NR^8R^5 ; and

 $\label{eq:Arisephenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{16}R^{15}$.}$

 (Currently amended) The compound of claim 16, or pharmaceutically acceptable sait thereof, wherein:

X is O;

Y is methylene or ethylene;

Z is O or absent;

Applicant: Brian Smith, et al. Serial No.: 10/576,849 Filed: April 9, 2007 Page: 11 of 24

R1 is H or Co-Ca alkyl:

R2 is methyl or ethyl;

R3 is H:

R4 and R6 are both H:

 R^5 is halo, C_1 - C_4 alkyl, C_1 - C_6 haloalkyl, hydroxy, C_1 - C_6 alkoxy, C_1 - C_6 haloalkoxy, evano, nitro, or NR^3R^9 : and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, hydroxy, C_1 - C_6 alkoxy, C_1 - C_6 haloalkoxy, or $NR^{16}R^{15}$.

20. (Original) The compound of claim 1 having Formula (IId):

$$R^5$$
 R^4
 R^2
 R^3
 $N-R^1$
 R^2
 R^3
 R^4
 R^2
 R^3
 $N-R^1$
 R^4
 R^2
 R^3

or pharmaceutically acceptable salt thereof.

(Currently amended) The compound of claim 20, or pharmaceutically acceptable salt thereof, wherein:

X is absent;

Y is methylene or ethylene:

Z is absent:

R1 is H or C1-C4 alkyl:

R² is methyl or ethyl;

R3 is H:

R4 and R5 are both H:

 R^{δ} is halo, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, hydroxy, C_1 - C_8 alkoxy, C_1 - C_8 haloalkoxy, evano, nitro, or NR^8R^9 ; and

 $Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoy, C_1-C_6 haloalkoxy, or $NR^{16}R^{15}$.}$

Applicant: Brian Smith, et al. Serial No.: 10/576.849

Attorney's Docket No.: 20750-0048US1 / 076 US2 PCT Filed : April 9, 2007 Page : 12 of 24

- 22. (Original) The compound of claim 1 selected from:
 - a) 1-methyl-8-(2-phenoxy-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - h) (4-fluoro-benzyl)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
 - biphenyl-4-ylmcthyl-(5-methyl-2.3,4,5-tctrahydro-1H-benzo[d]azepin-7-yl)c)

amine:

- 5-methyl-2,3,4,5-tetrahydro-1H-benzo(dlazepine-7-carboxylic acid phenylamide; d)
 - e) 5-methyl-2,3,4,5-tetrahydro-1H-benzo(dlazepine-7-carboxylic acid benzylamide;
- f) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid

phenethylamide:

- 5-methyl-2.3.4.5-tetrahydro-1H-benzofdlazenine-7-carboxylic acid 2) phenpropylamide;
- 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid 4h) phenylbenzylamide;
- [2-(3,4-dimethoxy-phenyl)-ethyl]-(5-methyl-2,3,4,5-tetrahydro-1H-(i benzo[d]azepin-7-yl)-amine;
 - j) 8-benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - k) indan-1'-vl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azenin-7-vl)-amine:
 - 7-benzyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; D)
 - m) 8-benzyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and
 - 6-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol; n)

or pharmaceutically acceptable salt thereof.

- 23. (Currently amended) The compound of claim 1 selected from:
 - a) 8-(3-Methoxy-benzyl)-1-methyl-2.3.4.5-tetrahydro-1H-benzofdlazepine;
 - 8-Benzyl-1-methyl-2.3.4.5-tetrahydro-1H-benzofdlazepine: b)
 - 8-Benzyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo(dlazenine; c)
 - 8-Benzyl-1-methyl-2.3.4.5-tetrahydro-1H-benzo(dlazepin-7-ol: d)
 - 1-Methyl-8-phenethyl-2.3.4.5-tetrahydro-1H-benzofdlazenine: e) n 8-(2-Fluoro-benzyl)-1-methyl-2.3.4.5-tetrahydro-1H-benzofdlazepine;
 - g) 8-(3-Fluoro-benzyl)-1-methyl-2.3.4.5-tetrahydro-1H-benzoldlazenine:
 - h) 8-(4-Fluoro-benzyl)-1-methyl-2.3.4.5-tetrahydro-1H-benzofd]azepine:

Applicant: Brian Smith, et al. Attorney's Docket No.: 20750-Serial No.: 10/576,849 0048US1 / 076 US2 PCT

Filed : April 9, 2007 Page : 13 of 24

> iì. 1-Methyl-8-(3-trifluoromethyl-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

8-(2,6-Diffuoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

(j k) 8-(2,4-diffuoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

D 8-(2,5-Diffuoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

8-(3,5-diffuoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; mì

8-(3,4-Diffuoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo(d)azepine; n)

8-(2-Methoxy-benzyl)-1-methyl-2.3,4,5-tetrahydro-1H-benzofd]azepine; 0)

p) 8-(4-Methoxy-benzyl)-1-methyl-2.3,4,5-tetrahydro-1H-benzold]azepine;

a) 1-Methyl-8-(1-phenyl-ethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

(8-Methoxy-5-methyl-2.3.4.5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenylr)

methanone:

- (5-Methyl-2.3.4.5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-methanone; s)
- 6-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol; ťì
- 12) 8-Benzyl-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- 8-G-Fluoro-henzyl)-1-methyl-2.3.4.5-tetrahydro-1H-benzofdlazepin-7-ol; and v)
- 7-(3-Fluoro-benzyloxy)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; w)

or pharmaceutically acceptable salt thereof acceptable salts.

24 (Currently amended) A composition comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

25. (Canceled)

26. (Currently amended) The method A method of treating a disorder of claim 25 wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorder[[s]], social phobia[[s or]], panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age related behavioral disorders, behavioral disorders associated with dementia, organic-mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, and obesity, bulimia;

Applicant : Brian Smith, et al. Attorney's Docket No.: 20750-Serial No.: 10/576,849 0048US1/076.US2.PCT

Filed : April 9, 2007 Page : 14 of 24

> anorexia nervesa and premenstrual tension comprising administering to a patient in need of said treating a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable sait thereof.

- (Currently amended) The method according to elaim 25 claim 26 wherein the disorder of the
 central nervous evotem is obesity.
- (Currently amended) The method according to elaim 25 claim 26 wherein the sexual dysfunction is male creetile dysfunction.
- (Currently amended) A method of decreasing food intake of a mammal comprising
 administering to said mammal a therapeutically effective amount of a compound of claim 1, or
 pharmaceutically acceptable sait thereof.
- (Currently amended) A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmacoutically acceptable salt thereof.
- (Currently amended) A method of controlling weight gain of a mammal comprising
 administering to said mammal a therapeutically effective amount of a compound of claim 1, or
 pharmaceutically acceptable salt thereof.

32-47. (Canceled)

- (Currently amended) A method for preparing a pharmaceutical composition comprising the step of mixing a compound[[st]] of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- (New) The method according to claim 26 wherein the disorder is depression.
- 50. (New) The method according to claim 26 wherein the disorder is anxiety.

 Applicant : Brian Smith, et al.
 Attorney's Docket No.: 20750

 Serial No. : 10/576,849
 0048USI / 076.US2.PCT

Filed : April 9, 2007 Page : 15 of 24

51. (New) The method according to claim 26 wherein the disorder is obsessive-compulsive disorder.

52. (New) The method according to claim 26 wherein the disorder is social phobia.

53. (New) The method according to claim 26 wherein the disorder is panic states.

54. (New) The method according to claim 26 wherein the disorder is psychoses.

55. (New) The method according to claim 26 wherein the disorder is schizophrenia.

 (New) The method according to claim 26 wherein the disorder is selected from drug and alcohol addiction.